文献速递主动脉疾病

非缺血性与缺血性复杂急性B型主动脉夹层的腔内治疗

Endovascular Therapy for Nonischemic vs Ischemic Complicated Acute Type B Aortic Dissection.
PubMed 文献 · J Endovasc Ther · 2019-12-04

单中心回顾性研究纳入64例接受TEVAR的复杂急性B型主动脉夹层患者,比较缺血性与非缺血性患者的预后。缺血组从诊断到治疗时间更短(2.3天 vs 7.5天,p=0.007),56%的缺血患者接受了肾血管分支支架。两组早期和晚期结局无统计学显著差异,30天死亡率分别为5%和16%。

要点

  • 缺血性复杂急性B型主动脉夹层应更早干预,诊断至治疗时间显著短于非缺血组。
  • TEVAR治疗复杂急性B型主动脉夹层技术成功率达97%,安全有效。
  • 缺血患者术中行分支血管支架直接再灌注可能对改善预后至关重要。

核心结论

  • TEVAR是治疗复杂急性B型主动脉夹层的有效且安全的方法。
  • 对缺血性复杂急性B型主动脉夹层早期干预可能对消除缺血与非缺血组结局差异起重要作用。
  • TEVAR术中通过分支血管支架直接行内脏再灌注可能对缺血性复杂急性B型主动脉夹层获得良好结局至关重要。

研究设计与样本

  • 患者平均年龄64.8±12.5岁,其中49例为男性。
  • 按有无终末器官缺血分为非缺血组39例(61%)和缺血组25例(39%)。

主要发现

  • 从诊断到治疗的平均时间非缺血组为7.5天(范围1-32天),缺血组为2.3天(范围1-14天),p=0.007。
  • 25例缺血性患者中14例(56%)在肾血管分支置入支架,4例(16%)在髂动脉置入支架;分支血管插管失败时在内膜片开窗以改善分支灌注(n=5)。
  • 非缺血组中3条动脉因动脉粥样硬化性狭窄而置入支架。
  • 技术成功62/64例(97%);尽管置入支架,2例患者最终造影显示肾动脉灌注低。
  • 30天内6例(9%)死亡:非缺血组2例(5%),缺血组4例(16%)。

临床怎么用

  • 对复杂急性B型主动脉夹层,尤其合并终末器官缺血者,应考虑尽早行TEVAR。
  • 缺血性患者术中可优先尝试分支血管支架置入以直接恢复内脏灌注,插管失败时可考虑内膜片开窗。

局限性

  • 单中心回顾性研究,样本量有限(64例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To report a single-center experience with thoracic endovascular aortic repair (TEVAR) for complicated acute type B aortic dissection (cATBAD) comparing patients with vs without end-organ ischemia. Materials and Methods: Between November 2010 and December 2017, 64 patients (mean age 64.8±12.5 years; 49 men) underwent TEVAR for cATBAD. Patients were grouped into 2 cohorts: nonischemic (39, 61%) patients with unrelenting pain, early progressive aortic dilatation, uncontrolled hypertension, or rupture, and ischemic (25, 39%) patients with visceral, renal, lower extremity, or spinal cord hypoperfusion. Results: Mean time from diagnosis to treatment was 7.5 days (range 1-32) in the nonischemic group vs 2.3 days (range 1-14) days in the ischemic group (p=0.007). Fourteen (56%) of 25 ischemic cATBAD patients had stents implanted in the renovascular branch vessels, while 4 (16%) patients had stents implanted in the iliac arteries. When branch vessel cannulation failed, fenestrations were made in the intimal flap to improve perfusion of the involved branch (n=5). In the nonischemic group, 3 arteries were stented owing to atherosclerotic stenosis. Technical success was achieved in 62 (97%) of 64 patients; despite stenting, 2 patients had low renal artery perfusion on final angiography. There were no statistically significant differences in early or late outcomes between the nonischemic vs ischemic cATBAD patients. Six (9%) patients died within 30 days: 2 (5%) in the nonischemic group vs 4 (16%) in the ischemic group. Major complications (1 stroke, 2 cases of paraplegia, 1 retrograde type A dissection, and 1 case of bowel ischemia) occurred only in the nonischemic group. The mean follow-up was 28 months. Late endoleaks were observed in 3 (8%) nonischemic patients and 1 (4%) ischemic patient. Reinterventions were required in 7 (18%) nonischemic patients and 4 (16%) ischemic patients. Conclusion: TEVAR is an effective and safe method of treating cATBAD. Early intervention in ischemic cATBAD may have played a significant role in the lack of significant difference between ischemic and nonischemic cATBAD outcomes. Direct visceral reperfusion through branch vessel stenting during TEVAR may be crucial in achieving good outcomes in ischemic cATBAD.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Eleshra A, Kölbel T, Panuccio G, et al. Endovascular Therapy for Nonischemic vs Ischemic Complicated Acute Type B Aortic Dissection. J Endovasc Ther. 2019. PMID: 31797707. doi:10.1177/1526602819888672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。